Summit Therapeutics Inc
SMMT17.640USD
-0.200-1.12%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
13.13BMarket Cap
LossP/E TTM
More Details of Summit Therapeutics Inc Company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Summit Therapeutics Inc Info
Ticker SymbolSMMT
Company nameSummit Therapeutics Inc
IPO dateOct 14, 2004
CEODr. Mahkam (Maky) Zanganeh
Number of employees159
Security typeOrdinary Share
Fiscal year-endOct 14
Address601 Brickell Key Drive
CityMIAMI
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code33131
Phone13052032034
Websitehttps://www.smmttx.com/
Ticker SymbolSMMT
IPO dateOct 14, 2004
CEODr. Mahkam (Maky) Zanganeh
Company Executives of Summit Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
570.07M
+2.51%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
570.07M
+2.51%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Latin America
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Duggan (Robert William)
76.58%
Zanganeh (Mahkam)
4.80%
Baker Bros. Advisors LP
4.53%
Xia (Yu)
4.23%
The Vanguard Group, Inc.
1.53%
Other
8.33%
Shareholders
Shareholders
Proportion
Duggan (Robert William)
76.58%
Zanganeh (Mahkam)
4.80%
Baker Bros. Advisors LP
4.53%
Xia (Yu)
4.23%
The Vanguard Group, Inc.
1.53%
Other
8.33%
Shareholder Types
Shareholders
Proportion
Individual Investor
86.05%
Investment Advisor
5.97%
Hedge Fund
5.15%
Investment Advisor/Hedge Fund
2.51%
Research Firm
0.52%
Sovereign Wealth Fund
0.19%
Pension Fund
0.08%
Bank and Trust
0.01%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
489
101.69M
13.66%
-7.67M
2025Q2
447
727.40M
97.94%
-484.11K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Duggan (Robert William)
556.09M
74.86%
+338.39K
+0.06%
Sep 11, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Baker Bros. Advisors LP
33.72M
4.54%
+9.30M
+38.07%
Jun 30, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
The Vanguard Group, Inc.
8.67M
1.17%
-2.97M
-25.49%
Jun 30, 2025
Fidelity Management & Research Company LLC
9.23M
1.24%
-84.25K
-0.90%
Jun 30, 2025
State Street Investment Management (US)
4.02M
0.54%
-833.69K
-17.18%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.92M
0.8%
-1.59M
-21.14%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.80M
0.51%
-2.66M
-41.13%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.93M
0.4%
-350.07K
-10.66%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Tema Oncology ETF
2.08%
SPDR S&P Biotech ETF
1.8%
ProShares Ultra Nasdaq Biotechnology
1.59%
Invesco Nasdaq Biotechnology ETF
1.55%
Direxion Daily S&P Biotech Bull 3X Shares
0.94%
Invesco NASDAQ Next Gen 100 ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
First Trust Health Care Alphadex Fund
0.39%
iShares Biotechnology ETF
0.22%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.17%
View more
Tema Oncology ETF
Proportion2.08%
SPDR S&P Biotech ETF
Proportion1.8%
ProShares Ultra Nasdaq Biotechnology
Proportion1.59%
Invesco Nasdaq Biotechnology ETF
Proportion1.55%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.94%
Invesco NASDAQ Next Gen 100 ETF
Proportion0.88%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.74%
First Trust Health Care Alphadex Fund
Proportion0.39%
iShares Biotechnology ETF
Proportion0.22%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proportion0.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Summit Therapeutics Inc?
The top five shareholders of Summit Therapeutics Inc are:
Duggan (Robert William) holds 556.09M shares, accounting for 74.86% of the total shares.
Zanganeh (Mahkam) holds 35.74M shares, accounting for 4.81% of the total shares.
Baker Bros. Advisors LP holds 33.72M shares, accounting for 4.54% of the total shares.
Xia (Yu) holds 31.52M shares, accounting for 4.24% of the total shares.
The Vanguard Group, Inc. holds 8.67M shares, accounting for 1.17% of the total shares.
Duggan (Robert William) holds 556.09M shares, accounting for 74.86% of the total shares.
Zanganeh (Mahkam) holds 35.74M shares, accounting for 4.81% of the total shares.
Baker Bros. Advisors LP holds 33.72M shares, accounting for 4.54% of the total shares.
Xia (Yu) holds 31.52M shares, accounting for 4.24% of the total shares.
The Vanguard Group, Inc. holds 8.67M shares, accounting for 1.17% of the total shares.
What are the top three shareholder types of Summit Therapeutics Inc?
The top three shareholder types of Summit Therapeutics Inc are:
Duggan (Robert William)
Zanganeh (Mahkam)
Baker Bros. Advisors LP
Duggan (Robert William)
Zanganeh (Mahkam)
Baker Bros. Advisors LP
How many institutions hold shares of Summit Therapeutics Inc (SMMT)?
As of 2025Q3, 489 institutions hold shares of Summit Therapeutics Inc, with a combined market value of approximately 101.69M, accounting for 13.66% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -84.29%.
What is the biggest source of revenue for Summit Therapeutics Inc?
In FY2023, the -- business generated the highest revenue for Summit Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
